Role of trisomy 21 mosaicism in sporadic and familial alzheimer’s disease

Current Alzheimer Research

Volumn 13, Issue 1, 2016, Pages 7-17

  Potter, Huntington ^a   Granic, Antoneta ^b   Caneus, Julbert ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Alzheimer s disease; Aneuploidy; Down syndrome; Mitosis; Neurogenesis; Trisomy 21

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CHOLESTEROL; PRESENILIN; LITHIUM CHLORIDE; PRESENILIN 1;

ALZHEIMER DISEASE; ANEUPLOIDY; APOPTOSIS; ARTICLE; CELL CYCLE; CHROMOSOME 14; CHROMOSOME 16; CHROMOSOME 21; CHROMOSOME LOSS; CHROMOSOME SEGREGATION; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; DOWN SYNDROME; FAMILIAL ALZHEIMER DISEASE; FRONTOTEMPORAL DEMENTIA; GENE DOSAGE; GENE MUTATION; GENETIC RISK; HUMAN; KARYOTYPING; MITOSIS; MITOSIS SPINDLE; MOSAICISM; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SPORADIC ALZHEIMER DISEASE; TRISOMY 12; TRISOMY 21; ANIMAL; DRUG EFFECTS; GENETICS; METABOLISM; MOUSE; NERVE CELL; PATHOLOGY; TRISOMY; UNIPARENTAL DISOMY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; CELL CYCLE; CHROMOSOMES, HUMAN, PAIR 21; HUMANS; LITHIUM CHLORIDE; MICE; MOSAICISM; NEURONS; PRESENILIN-1; TRISOMY; UNIPARENTAL DISOMY;

EID: 84953450010     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720501301151207100616     Document Type: Article

References (172)

1. Wisniewski HM, Rabe A, Wisniewski KE. Neuropathology and dementia in people with Down's syndrome. In: Davies P, Finch C, Eds., Mol Neuropathol Aging pp. 399-413 (1988).
2. Epstein CJ. The consequences of chromosome imbalance. Am J Med Genet: Suppl. 7: 31-37 (1990).
3. Lott IT. Neurological phenotypes for Down syndrome across the life span. Prog Brain Res 197: 101-121 (2012).
4. Lemere CA, Blusztajn JK, Yamaguchi H, Wisniewski T, Saido TC, Selkoe DJ. Sequence of deposition of heterogeneous amyloid betapeptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol Dis 3(1): 16-32 (1996).
5. Olson MI, Shaw CM. Presenile dementia and Alzheimer's disease in mongolism. Brain 92(1): 147-156 (1969).
6. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297(5580): 353-356. Review. Erratum in: Science 297(5590): 2209 (2002).
7. Glenner G, Wong CW. Alzheimer disease and Down's syndrome: Sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun 122: 1131-1135 (1984).
8. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 82(12): 4245-4249 (1985).
9. Goldgaber D, Lerman MJ, McBride OW, Saffiotti U, Gajdusek DC. Characterization and chromosomal localization of cDNA encoding brain amyloid of Alzheimer's disease. Science 235(4791): 877-880 (1987).
10. Neve RL, Finch EA, Dawes LR. Expression of the Alzheimer amyloid precursor gene transcripts in the human brain. Neuron 1(8): 669-677 (1988).
11. Petterson D, Gardiner K, Kao FT, Tanzi R, Watkins P, Gusella JF. Mapping of the gene encoding the β-amyloid precursor protein and its relationship to the Down syndrome region of chromosome 21. Proc Nat Acad Sci USA 85(21): 8266-8270 (1988).
12. Tanzi RE, Gusella JF, Watkins PC, Bruns GA, St George-Hyslop P, Van Keuren ML, et al. Amyloid β-protein gene cDNA, mRNA distributions, and genetic linkage near the Alzheimer locus. Science 235(4791): 880-884 (1987).
13. Blennow K, de Leon M, Zetterberg H. Alzheimer's disease. Lancet 368(9533): 387-403 (2006).
14. Lee VM, Trojanowski JQ. Progress from Alzheimer's tangles to pathological tau points towards more effective therapies now. J Alzheimers Dis 9: 257-262 (2006).
15. Hardy J. Alzheimer's disease: the amyloid cascade hypothesis: an update and reappraisal. Alzheimers Dis 9(3): 151-153 (2006).
16. Ma J, Yee A, Brewer HB, Das S, Potter H. The Alzheimer amyloid-associated proteins a1-antichymotrypsin and apolipoprotein E promote the assembly of the Alzheimer β-protein into filaments. Nature 372: 92-94 (1994). (see also "News and Views," same issue).
17. Wisniewski T, Castano EM, Golabek A, Vogel T, Frangione B. Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am J Pathol 145: 1030-1035 (1994).
18. Bales KR, Verina T, Dodel RC, Du Y, Altstiel L, Bender M, et al. Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition. Nat Genet 17: 263-264 (1997).
19. Holzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius L, et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 97: 2892-2897 (2000).
20. Mucke L, Yu G-Q, McConlogue L, Rockenstein EM, Abraham CR, Masliah E. Astroglial expression of human α1-antichymotrypsin enhances Alzheimer-like pathology in amyloid protein precursor transgenic mice. Am J Pathol 157: 2003-2010 (2000).
21. Nilsson LNG, Bales KR, DiCarlo D, Gordon MN, Morgan D, Paul SM, et al. α-1-antichymotrypsin promotes beta-sheet amyloid plaque deposition in transgenic mouse model of Alzheimer's disease. J Neurosci 21: 1444-1451 (2001).
22. Nilsson LNG, Gografe S, Costa DA, Hughes T, Dressler D, Potter H. Use of fused circulations to investigate the role of apolipoprotein E as amyloid catalyst and peripheral sink in Alzheimer's disease. Technol Innov 14: 199-208 (2012).
23. Potter H, Wisniewski T. Apolipoprotein E: Essential Catalyst of the Alzheimer Amyloid Cascade. Intern Alz Dis 2012: 489428 (2012).
24. Roses AD. Apolipoprotein E alleles as risk factor in Alzheimer's disease. Annu Rev Med 47: 387-400 (1996).
25. Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, et al. Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci Transl Med 3(89): 89ra57 (2011).
26. Roberson ED. Mouse models of frontotemporal dementia. Ann Neurol 72(6): 837-849 (2012).
27. Cohen R, Rezai-Zadeh K, Weitz TM, Rentsendorj A, Gate D, Spivak I, et al. A transgenic Alzheimer rat with plaques, tau pathology, behavioral impairment, oligomeric aβ, and frank neuronal loss. J Neurosci 33(15): 6245-6256 (2013).
28. Hartley D, Blumenthal T, Carrillo M, DiPaolo G, Esralew L, Gardiner K, et al. Down syndrome and Alzheimer's disease: Common pathways, common goals. Alzheimers Dement 11(6): 700-709 (2015).
29. Rovelet-Lecrux A, Hannequin D, Raux G, Le Meur N, Laquerriere A, Vital A, et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet 38(1): 11-12 (2006).
30. Sleegers K, Brouwers N, Gijselinck I, Theuns J, Goossens D, Wauters J, et al. APP duplication is sufficient to cause early onset Alzheimer's dementia with cerebral amyloid angiopathy. Brain 129(11): 2977-2983 (2006).
31. Schweber M. A possible unitary genetic hypothesis for Alzheimer's disease and Down syndrome. Ann NY Acad Sci 450: 223-238 (1985).
32. Prasher VP, Farrer JM, Kessling AM, Fisher EM, West RJ, Barber PC, et al. Molecular mapping of Alzheimer-type dementia in Down's syndrome. Ann Neurol 43: 380-383 (1998).
33. Potter H. Review and hypothesis: Alzheimer disease and Down syndrome--chromosome 21 nondisjunction may underlie both disorders. Am J Hum Genet 48(6): 1192-1200 (1991).
34. Hulten MA, Jonasson J, Nordgren A, Iwarsson E. Germinal and somatic trisomy 21 mosaicism: how common is it, what are the implications for individual carriers and how does it come about? Curr Genom 11(6): 1389-2029 (2010).
35. Schapiro MB, Kumar A, White B, Grandy CL, Friedland RP, Rappaport SI. Alzheimer's disease (AD) in mosaic/translocation Down's syndrome (Ds) without mental retardation. Neurology 39: 169 (1989).
36. Rowe IF, Ridler MAC, Gibberd FB. Presenile dementia associated with mosaic trisomy 21 in a patient with a Down syndrome child. Lancet 2(8656): 229 (1989).
37. Hardy J, Goate A, Owen M, Rossor M. Presenile dementia associated with mosaic trisomy 21 in a patient with a Down syndrome child. Lancet 2(8665): 743 (1989).
38. Ringman JM, Rao PN, Lu PH, Cederbaum S. Mosaicism for trisomy 21 in a patient with young-onset dementia: a case report and brief literature review. Arch Neurol 65(3): 412-415 (2008).
39. Jarvik LF, Yen F-S, Goldstein F. Chromosomes and mental status. A study of women residing in institutions for the elderly. Arch Gen Psychiatry 30: 186-190 (1974).
40. Ward BE, Cook RH, Robinson A, Austin JH. Increased aneuploidy in Alzheimer disease. Am J Med Genet 3: 137-144 (1979).
41. Nordenson I, Adolfsson R, Beckman G, Bucht G, Winblad B. Chromosomal abnormality in dementia of Alzheimer type. Lancet 1: 481-482 (1980).
42. White BJ, Crandall C, Goudsmit J, Morrow CH, Alling DW, Gajdusek DC, et al. Cytogenetic studies of familial and sporadic Alzheimer disease. Am J Med Genet 10: 77-89 (1981).
43. Buckton KE, Whalley LJ, Lee M. Chromosome changes in Alzheimer's presenile dementia. J Med Genet 20: 46-51 (1983).
44. Moorhead PS, Heyman A. Chromosome studies of patients with Alzheimer's disease. Am J Med Genet 14: 545-556 (1983).
45. Kormann-Bortolotto MH, Smith MAC, Neto JT. Alzheimer's disease and ageing: a chromosomal approach. Gerontology 39: 1-6 (1993).
46. Lao JI, Beyer K, Fernadez-Novoa L. Cytogenetic signs of genomic instability in Alzheimer's disease. Neurobiol Aging 17: S62 (1996).
47. Potter H, Ma J, Das S, Geller LN, Benjamin M, Kayyali US, et al. Beyond β-protein: new steps in the pathogenic pathway to Alzheimer's disease. In: Iqbal K, Mortimer JA, Winblad B, Wisnicuski HM, Eds. Research Advances in Alzheimer's Disease and Related Disorders. New York: John Wiley and Sons 643-654 (1995).
48. Potter H, Geller LN. Alzheimer disease, Down's syndrome, and chromosome segregation. Lancet 348: 66 (1996).
49. Geller LN, Potter H. Chromosome missegregation and trisomy 21 mosaicism in Alzheimer's disease. Neurobiol Dis 6(3): 167-179 (1999).
50. Migliore L, Testa A, Scarpato R, Pavese N, Petrozzi L, Bonuccelli U. Spontaneous and induced aneuploidy in peripheral blood lymphocytes of patients with Alzheimer's disease. Hum Genet 101(3): 299-305 (1997).
51. Migliore L, Botto N, Scarpato R, Petrozzi L, Cipriani G, Bonuccelli U. Preferential occurrence of chromosome 21 malsegregation in peripheral blood lymphocytes of Alzheimer disease patients. Cytogenet Cell Genet 87(1-2): 41-46 (1999).
52. Thomas P, Fenech M. Chromosome 17 and 21 aneuploidy in buccal cells is increased with ageing and in Alzheimer's disease. Mutagenesis 23(1): 57-65 (2008).
53. Kingsbury MA, Yung YC, Peterson S E, Westra JW, Chun J. Aneuploidy in the normal and diseased brain. Cell Mol Life Sci 63: 2626-2641 (2006).
54. Mosch B, Morawski M, Mittag A, Lenz D, Tarnok A, Arendt T. Aneuploidy and DNA replication in the normal human brain and Alzheimer's disease. J Neurosci 27(26): 6859-6867 (2007).
55. Iourov IY, Vorsanova SG, Liehr T, Yurov YB. Aneuploidy in the normal, Alzheimer's disease and ataxia-telangiectasia brain: differential expression and pathological meaning. Neurobiol Dis 34(2): 212-220 (2009a).
56. Arendt T, Bruckner MK, Mosch B, Losche A. Selective cell death of hyperploid neurons in Alzheimer's disease. Am J Pathol 177(1): 15-20 (2010).
57. Arendt T. Cell cycle activation and aneuploid neurons in Alzheimer's disease. Mol Neurobiol 46: 125-135 (2012).
58. Heston LL, Mastri AR. The genetics of Alzheimer's disease. Arch Gen Psychiatry 34: 976-981 (1977).
59. Heston LL, Mastri AR, Anderson VE, White J. Dementia of the Alzheimer type. Arch Gen Psychiatry 38: 1084-1090 (1981).
60. Heyman A, Wilkinson W, Hurwitz B, Schmechel D, Sigmon AH, Weinberg T, et al. Alzheimer's disease: Genetic aspects and associated clinical disorders. Ann Neurol 14: 507-515 (1983).
61. Whalley LJ, Carothers AD, Collyer S, De Mey R, Frackiewicz A. A study of familial factors in Alzheimer's disease. Br J Psychiatry 140: 249-256 (1982).
62. Amaducci LA, Fratiglioni L, Rocca WA, Fieschi C, Livrea P, Pedone D, et al. Risk factors for clinically diagnosed Alzheimer's disease: A case-control study of an Italian population. Neurology 36: 922-931 (1986).
63. Chandra V, Philipose V, Bell PA, Lazaroff A, Schoenberg BS. Case-control study of late onset "probable Alzheimer's disease." Neurology 37: 1295-1300 (1987).
64. Schupf N, Kapell D, Lee JH, Ottman R, Mayeux R. Increased risk of Alzheimer's disease in mothers of adults with Down's syndrome. Lancet 344(8919): 353-356 (1994).
65. Schupf N, Kapell D, Naghtingale B, Lee JH, Mohlenhoff J, Bewley S, et al. Specificity of the fivefold increase in AD in mothers of adults with Down syndrome. Neurology 57(6): 979-984 (2001).
66. Migliore L, Boni G, Bernardini F, Trippi F, Colognato R, Fontana I, et al. Susceptibility to chromosome malsegregation in lymphocytes of women who had a Down syndrome child in young age. Neurobiol Aging 27(5): 710-716 (2006).
67. Migliore L, Migheli F, Coppede F. Susceptibility to aneuploidy in young mothers of Down syndrome children. Scientific World J 9: 1052-1060 (2009).
68. Migliore L, Coppede F, Fenech M, Thomas P. Association of micronucleus frequency with neurodegenerative diseases. Mutagenesis 26(1): 85-92 (2011).
69. Fitzgerald PH, Archer SA, Morris CM. Evidence for the repeated primary non-disjunction of chromosome 21 as a result of premature centromere division (PCD). Hum Genet 72(1): 58-62 (1986).
70. Spremo-Potparević B, Živković L, Djelić N, Plećas-Solarović B, Smith MA, Bajić V. Analysis of premature centromere division (PCD) of the chromosome 18 in peripheral blood lymphocytes in Alzheimer disease patients. Mech Ageing Develop 127: 892-896 (2006).
71. Spremo-Potparević B, Živković L, Djelić N, Plećas-Solarović B, Smith MA, Bajić V. Premature centomere division of the X chromosome in neurons in Alzheimer's disease. J Neurochem 106(5): 2218-2223 (2008).
72. Ford JH. Spindle microtubular dysfunction in mothers of Down syndrome children. Hum Genet 68: 295-298 (1984).
73. Staessen C, Maes AM, Kirsch-Volders M, Susanne C. Is there a predisposition for meiotic non-disjunction that may be detected by mitotic hyperploidy? Clin Genet 24: 184-190 (1983).
74. Schellenberg GD, Bird TD, Wijsman EM, Orr HT, Anderson L, Nemens E, et al. Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14. Science 258: 668-671 (1993).
75. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375: 754-760 (1995).
76. Levy-Lahad E, Wijsman EM, Nemens E, Anderson L, Goddard KA, Weber JL, et al. A familial Alzheimer's disease locus on chromosome. Science 269: 970-973 (1995a).
77. Levy-Lahad E, Wasco W, Poorkaj P, Ramano Dm, Oshima J, Pettingell WH, et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 269: 973-977 (1995b).
78. Rogaev EI, Sherrington R, Rogaeva EA, Levesque G, Ikeda M, Liang Y, et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 376: 775-778 (1995).
79. Li J, Ma J, Potter H. Identification and expression analysis of a potential familial Alzheimer's disease gene on chromosome 1 related to AD3. Proc Natl Acad Sci USA 92: 12180-12184 (1995).
80. Xia D, Watanabe H, Wu B, Lee SH, Li Y, Tsvetkov, E, et al. Presenilin-1 knockin mice reveal loss-of-function mechanism for familial Alzheimer's disease. Neuron 85: 967-981 (2015).
81. Li J, Xu M, Zhou H, Ma J, Potter H. Alzheimer presenilins in the nuclear membrane, interphase kinetochores, and centrosomes suggest a role in chromosome segregation. Cell 90: 917-927 (1997).
82. Annaert WG, Levesque L, Craessaerts K, Dierinck I, Snellings G, Westaway D, et al. Presenilin 1 controls gamma-secretase processing of amyloid precursor protein in pre-golgi compartments of hippocampal neurons. J Cell Biol 147: 277-294 (1999).
83. Honda T, Nihonmatsu N, Yasutake K, Ohtake A, Sato K, Tanaka S, et al. Familial Alzheimer's disease-associated mutations block translocation of full-length presenilin 1 to the nuclear envelope. Neurosci Res 37: 101-111 (2000).
84. Kimura N, Nakamura SI, Honda T, Takashima A, Nakayama H, Ono F, et al. Age-related changes in the localization of presenilin-1 in cynomolgus monkey brain. Brain Res 922: 30-41 (2001).
85. Nizzari M, Venezia V, Bianchini P, Caorsi V, Diaspro A, Repetto E, et al. Amyloid precursor protein and presenilin 1 interaction studied by FRET in human H4 cells. Ann NY Acad Sci 1096: 249-257 (2007).
86. Young-Pearse TL, Suth S, Luth ES, Sawa A, Selkoe DJ. Biochemical and functional interaction of disrupted-in-schizophrenia 1 and amyloid precursor protein regulates neuronal migration during mammalian cortical development. J Neurosci 30(31): 10431-10440 (2010).
87. Judge M, Hornbeck L, Potter H, Padmanabhan J. Mitosis-specific phosphorylation of amyloid precursor protein at threonine 668 leads to its altered processing and association with centrosomes. Mol Neurodegen 6: 80 (2011).
88. Jeong SJ, Kim HS, Chang KA, Geum DH, Park CH, Seo JH, et al. Subcellular localization of presenilins during mouse preimplantationdevelopment. FASEB 14: 2171-2176 (2000).
89. Kulnane LS, Lehman EJ, Hock BJ, Tsuchiya KD, Lamb BT. Rapid and efficient detection of transgene homozygosity by FISH of mouse fibroblasts. Mamm Genom 13(4): 223-226 (2002).
90. Boeras DI, Granic A, Crespo NC, Rojiani AM, Potter H. Alzheimer's presenilin 1 causes chromosome missegregation and aneuploidy. Neurobiol Aging 29(3): 319-328 (2008).
91. Granic A, Padmanabhan J, Norden M, Potter H. Alzheimer Aβ peptide induces chromosome mis-segregation and aneuploidy, including trisomy 21: requirement for tau and APP. Mol Biol Cell 21(4): 511-520 (2010).
92. Potter H. Down syndrome and Alzheimer's disease: two sides of the same coin. Future Neurol (1)29-37: 1479-6708 (2008).
93. Small SA, Duff K. Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron 60(4): 534-542 (2008).
94. Rapoport M, Dawson HN, Binder LI, Vitek MP, Ferreira A. Tau is essential to beta-amyloid-induced neurotoxicity. Proc Natl Acad Sci USA 99(9): 6364-6369 (2002).
95. Borysov SI, Granic, A, Padmanabhan J, Potter H. Alzheimer Aβ disrupts the mitotic spindle by inhibiting mitotic motors. Cell Cycle 10(9): 1397-1410 (2011).
96. Iourov IY, Vorsanova SG, Liehr T, Kolotii AD, Yurov YB. Increased chromosome instability dramatically disrupts neural genome integrity and mediates cerebellar degeneration in the ataxiatelangiectasia brain. Hum Mol Genet 18: 2656-2669 (2009b).
97. Yang, Y, Shepherd, D, Halliday, G. Aneuploidy in Lewy body diseases. Neurobiol Aging 36(3): 1253-1260 (2015).
98. Rossi G, Dalpra L, Crosti F, Lissoni S, Sciacca FL, Catania M, et al. A new function of microtubule-associated protein tau: involvement in chromosome stability. Cell Cycle 15: 1788-1794 (2008).
99. Rossi G, Conconi D, Panzeri E, Redaelli S, Piccoli E, Paoletta L. Mutations in MAPT gene cause chromosome instability and introduce copy number variations widely in the genome. J Alzheimers Dis 33: 969-982 (2013).
100. Rossi G, Conconi D, Panzeri E, Paoletta L, Piccoli E, Ferretti MG, et al. Mutations in MAPT give rise to aneuploidy in mouse models of tauopathy. Neurogenetics 15: 31-40 (2014).
101. Busciglio J, Yankner BA. Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro. Nature 378: 776-779 (1997).
102. McConnell MJ, Kaushal D, Yang AH, Kingsbury MA, Rehen SK, et al. Failed clearance of aneuploid embryonic neural progenitor cells leads to excess aneuploidy in the Atm-deficient but not the Trp53-deficient adult cerebral cortex. J Neurosci 241(37): 8090-8096 (2004).
103. Rajendran RS, Wellbrock UM, Zupanc GK. Apoptotic cell death, long-term persistence, and neuronal differentiation of aneuploid cells generated in the adult brain of teleost fish. Dev Neurobiol 68: 1257-1268 (2008).
104. Kai Y, Wang CC, Kishigami S, Kazuki Y, Abe S, Takiguchi M, Treunes K, et al. Enhanced apoptosis during early neuronal differentiation in mouse ES cells with autosomal imbalance. Cell Res 19: 247-258 (2009).
105. Peterson S, Yang AH, Bushman DM, Westra JW, Yung YC, Baral S, et al. Aneuploid cells are differentially susceptible to caspasemediated death during embryonic cerebral cortical development. J Neurosci 32(46): 16213-16222 (2012).
106. Oromendia AB, Amon A. Aneuploidy: implications for protein homeostasis and disease. Dis Model Mech 7: 15-20 (2014).
107. Sparks DL. Coronary artery disease, hypertension, ApoE, and cholesterol: a link to Alzheimer's disease. Ann NY Acad Sci 826: 128-146 (1997).
108. Burns M, Duff K. Cholesterol in Alzheimer's disease and tauopathy. Ann NY Acad Sci 977: 367-375 (2002).
109. Wolozin B. Cholesterol and the biology of Alzheimer's disease. Neuron 41: 7-10. (2004).
110. Anstey KJ, Lipnicki DM, Low LF. Cholesterol as a risk factor for dementia and cognitive decline: A systematic review of prospective studies with meta-analysis. Am J Geriatr Psychiatry 16: 343-354 (2008).
111. Dolan H, Crain B, Troncoso J, Resnik SM, Zonderman AB, O'Brien R. Atherosclerosis, dementia, and Alzheimer's disease in the Baltimore Longitudinal Study of Aging Cohort. Ann Neurol 68: 231-240 (2010).
112. Vance J. Dysregulation of cholesterol balance in the brain: contribution to neurodegenerative disease. Dis Model Mech 5: 746-755 (2012).
113. Sparks DL, Hunsaker JC, Scheff SW, Kryscio RJ, Henderson JL, Markersbery WR. Cortical senile plaques in coronary artery disease, aging and Alzheimer's disease. Neurobiol Aging 11: 601-607 (1990).
114. Beach TG, Wilson JR, Sue LI, Newell A, Poston M, Cisneros R. Circle of Willis atherosclerosis: association with Alzheimer's disease, neuritic plaques and neurofibrillary tangles. Acta Neuropathol 113: 13-21 (2007).
115. Casalone R, Granata P, Minelli E, Portentoso P, Giudici A, Righi R, et al. Cytogenetic analysis reveals clonal proliferation of smooth muscle cells in atherosclerotic plaques. Hum Genet 87: 139-143 (1991).
116. Vanni R, Licheri S. Clonal cytogenetic changes in atherosclerotic plaques including trisomy 20. Dis Markers 9: 81-85 (1991).
117. Matturri L, Cazzullo A, Turconi P, Lavezzi AM. Cytogenetic aspects of cell proliferation in atherosclerotic plaques. Cardiologia 42: 833-836 (1997).
118. Matturri L, Cazzullo A, Turconi P, Lavezzi AM, Vandone PR, Gabrielli L, et al. Chromosomal alterations in atherosclerotic plaques. Atherosclerosis 154: 755-761 (2001).
119. Murry CE, Gipaya CT, Bartosek T, Benditt EP, Schwartz SM. Monoclonality of smooth muscle cells in human atherosclerosis. Am J Pathol 151: 697-705 (1997).
120. Andreassi MG, Botto N, Colombo MG, Biagini A, Clerico A. Genetic instability and atherosclerosis: can somatic mutations account for the development of cardiovascular diseases? Environ Mol Mutagen 35: 265-269 (2000).
121. Miniati P, Sourvinos G, Michalodimitrakis M, Spandidos DA. Loss of heterozygosity on chromosomes 1, 2, 8, 9 and 17 in cerebral atherosclerotic plaques. Int J Biol Markers 16: 167-171 (2001).
122. Granic A, Potter H. Cholesterol induces mitotic spindle disruption and chromosome mis-segregation-implications for Niemann Pick, cardiovascular, and Alzheimer's disease. PLoS One 8(4): e60718 (2013).
123. Jin LW, Maezawa I, Vincent I, Bird T. Intracellular accumulation of amyloidogenic fragments of amyloid-b precursor protein in neurons with niemann-pick type c defects is associated with endosomal abnormalities. Am J Pathol 164(3): 975-985 (2004).
124. Granic A, Potter H. Down syndrome model of Alzheimer's disease: beyond trisomy 21 nondisjunction. In: Dey S, Ed. Genetics and etiology of Down syndrome. Rijeka: In Tech pp. 159-176 (2011).
125. Rehen SK, McConnell MJ, Kaushal D, Kingsbury MA, Yang AH, Chun J. Chromosomal variation in neurons of the developing and adult mammalian nervous system. Proc Natl Acad Sci USA 98: 13361-13366 (2001).
126. Yang Y, Geldmacher DS, Herrup K. DNA replication precedes neuronal cell death in Alzheimer's disease. J Neurosci 21: 2661-2668 (2001).
127. Arendt T, Holzer M, Grossmann A, Zedlick D, Bruckner MK. Increased expression and subcellular translocation of the mitogen activated protein kinase and mitogen-activated protein kinase in Alzheimer's disease. Neuroscience 68: 5-18 (1995)
128. Arendt T, Rodel L, Gartner U, Holzer M. Expression of the cyclindependent kinase inhibitor p16 in Alzheimer's disease. Neuro Report 7: 3047-3049 (1996).
129. Smith TW, Lippa CF. TI Ki-67 immunoreactivity in Alzheimer's disease and other neurodegenerative disorders. J Neuropathol Exp Neurology 54: 297-303 (1995).
130. Vincent I, Rosado M, Davies P. Mitotic mechanisms in Alzheimer's disease? J Cell Biol 132: 413-425 (1996).
131. Vincent I, Jicha G, Rosado M, Dickson DW. Aberrant expression of mitotic Cdc2/cyclin B1 kinase in degenerating neurons of Alzheimer's disease brain. J Neurosci 17: 3588-3598 (1997).
132. McShea A, Harris PLR, Webster KR, Wahl AF, Smith MA. Abnormal expression of the cell cycle regulators P16 and CDK4 in Alzheimer's disease. Am J Pathol 150: 1933-1939 (1997).
133. Song J, Wang S, Tan M, Jia J. G1/S checkpoint proteins in peripheral blood lymphocytes are potentially diagnostic biomarkers for Alzheimer's disease. Neurosci Lett 526(2):144-1449 (2012).
134. Majd S, Zarifkar A, Rastegar K, Takhshid MA. Different fibrillar Abeta 1-42 concentrations induce adult hippocampal neurons to reenter various phases of the cell cycle. Brain Res 1218: 224-229 (2008).
135. Seward ME, Swanson E, Norambuena A, Reimann A, Cochran JN, Li R, et al. Amyloid-beta signals through tau to drive ectopic neuronal cell cycle re-entry in Alzheimer's disease. J Cell Sci 126(Pt 5): 1278-1286 (2013).
136. Absalon S, Kochanek DM, Raghavan V, Krichevsky AM. MiR-26b, upregulated in Alzheimer's disease, activates cell cycle entry, tau-phosphorylation, and apoptosis in postmitotic neurons. J Neurosci 33(37): 14645-14659 (2013).
137. Lopes JP, Blurton-Jones M, Yamasaki TR, Agostinho P, LaFerla FM. Activation of cell cycle proteins in transgenic mice in response to neuronal loss but not amyloid-beta and tau pathology. J Alzheimers Dis 16: 541-549 (2009).
138. Altman J, Das GD. Autoradiographic and histologic evidence of postnatal neurogenesis in rats. J Comp Neurol 124: 319-335 (1965).
139. Kaplan MS, Hinds JW. Neurogenesis in the adult rat: electron microscopic analysis of light radioautographs. Science 197: 1092-1094 (1977).
140. Bayer SA, Yackel JW, Puri PS. Neurons in the rat dentate gyrus granular layer substantially increase during juvenile and adult life. Science 216: 890-892 (1982).
141. Cameron HA, Woolley CS, McEwen BS, Gould E. Differentiation of newly born neurons and glia in the dentate gyrus of the adult rat. Neuroscience 56: 337-344 (1993).
142. Kaplan MS, Bell DH. Mitotic neuroblasts in the 9-day-old and 11-month-old rodent hippocampus. J Neurosci 4: 1429-1441 (1984).
143. Kuhn GH, Dickinson-Anson H, Gage FH. Neurogenesis in the dentate gyrus of the adult rat: age-related decrease of neuronal progenitor proliferation. J Neurosci 16(6): 2027-2033 (1996).
144. Gould E, Reeves AJ, Graziano MS, Gross CG. Neurogenesis in the neocortex of adult primates. Science 286: 548-52 (1999a).
145. Gould E, Reeves AJ, Fallah M, Tanapat P, Gross CG, Fuchs E. Hippocampal neurogenesis in adult Old World primates. Proc Natl Acad Sci USA 96: 5263-7 (1999b).
146. Mu Y, Gage FH. Adult hippocampal neurogenesis and its role in Alzheimer's disease. Mol Neurodegen 6: 85 (2011).
147. Ernst A, Alkass K, Bernard S, Salehpour M, Perl S, Tisdale J, et al. Neurogenesis in the striatum of the adult human brain. Cell 156(5): 1072-1083 (2014).
148. Zhou L, Del Villar K, Dong Z, Miller CA. Neurogenesis response to hypoxia-induced cell death: map kinase signal transduction mechanisms. Brain Res 1021(1): 8-19 (2004).
149. Zhao C, Deng W, Gage FH. Mechanisms and functional implications of adult neurogenesis. Cell 132: 645-660 (2008).
150. Spalding KL, Bergmann O, Alkass K, Bernard S, Salehpour M, Huttner HB, et al. Dynamics of hippocampal neurogenesis in adult humans. Cell 153: 1219-1227 (2013).
151. LeBlank A. Increased production of 4KDa amyloid beta peptide in serum-deprived human primary neuron cultures: possible involvement of apoptosis. J Neurosci 15: 7837-7846 (1995).
152. Galli C, Piccini A, Ciotti MT, Castellani L, Calissano P, Zaccheo D, et al. Increased amyloidogenic secretion in cerebellar granule cells undergoing apoptosis. Proc Natl Acad Sci USA 95: 1247-1252 (1998).
153. Bushman DM, Kaeser GE, Siddoway B, Westra JW, Rivera RR, Rehen SK, et al. Genomic mosaicism with increased amyloid precursor protein (APP) gene copy number in single neurons from sporadic Alzheimer's disease brains. Elife 4 (2015).
154. Griffin WST, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ, et al. Brain interleukin-1 and S100 immunoreactivity elevated in Down's syndrome and Alzheimer's disease. Proc Natl Acad Sci USA 86: 7611-7615 (1989).
155. Das S, Potter H. Expression of the Alzheimer amyloid-promoting factor antichymotrypsin is induced in human astrocytes by IL-1. Neuron 14: 447-456 (1995).
156. Parry EM, Parry JM, Corso C, Doherty A, Haddad F, Hermine TF et al. Detection and characterization of mechanisms of action of aneugenic chemicals. Mutagenesis 17(6): 509-521 (2002).
157. Hernandez LG, van Benthem J, Johnson GE. A mode-of-action approach for the identification of genotoxic carcinogens. PLoS One 8(5): e64532 (2013).
158. Nunes PV, Forlenza OV, Gattaz WF. Lithium and risk for Alzheimer's disease in elderly patients with bipolar disorder. Br J Psychiatry 190: 359-360 (2007).
159. Kessing LV, Sondergard L, Forman JL, Andersen PK. Lithium treatment and risk of dementia. Arch Gen Psychiatry 65(11): 1331-1335 (2008).
160. Forlenza OV, Diniz BS, Radanovic M, Santos FS, Talib LL, Gattaz WF. Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. Br J Psychiatry 198(5): 351-356 (2011)
161. Alvarez G, Munoz-Montano JR, Satrustegui J, Avila J, Bogonez E, Diaz-Nido J. Regulation of tau phosphorylation and protection against beta-amyloid-induced neurodegeneration by lithium. Possible implications for Alzheimer's disease. Bipolar Disord 4(3): 153-165 (2002).
162. Zhang X, Heng X, Li T, Li L, Yang D, Zhang X, et al. Long-term treatment with lithium alleviates memory deficits and reduces amyloid-β production in an aged Alzheimer's disease transgenic mouse model. J Alzheimers Dis 24(4): 739-749 (2011).
163. Hampel H, Ewers M, Burger K, Annas P, Mortberg A, Bogstedt A, et al. Lithium trial in Alzheimer's disease: a randomized, singleblind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry 70(6): 922-931 (2009).
164. Nunes MA, Viel TA, Buck HS. Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer's disease. Curr Alzheimer Res 10(1): 104-107 (2013).
165. Takashima, A. GSK-3 is essential in the pathogenesis of Alzheimer's disease. J Alzheimer's Dis 9: 309-317 (2006).
166. Kremer A, Louis JV, Jaworski T, Van Leuven F. GSK3 and Alzheimer's disease: facts and fiction. Front Mol Neurosci 4: 1-10 (2011).
167. King MK, Pardo M, Cheng Y, Downey K, Jope RS, Beurel E. Glycogen synthase kinase-3 inhibitors: rescuers of cognitive impairments. Pharmacol Ther 141(1): 1-12 (2014).
168. Abisambra JF, Fiorelli T, Padmanabhan J, Neame P, Wefes I, Potter H. LDLR expression and localization are altered in and in vivo and in vitro models of Alzheimer's disease. PLoS One 5: e8556 (2010).
169. Ari A, Borysov SI, Wu J, Padmanabhan J, Potter H. Alzheimer Ab inhibition of Eg5/kinesin5 disrupts neurotrophin and neurotransmitter receptor localization and function. Neurobiol Aging 35: 1839-1849 (2014).
170. Nadar VC, Ketschek A, Myers KA, Gallo G, Baas PW. Kinesin-5 is essential for growth-cone turning. Curr Biol 18: 1972-1977 (2008).
171. Falnikar A, Tole S, Baas PW. Kinesin-5, a mitotic microtubuleassociated motor protein, modulates neuronal migration. Mol Biol Cell 2: 1561-1574 (2011).
172. Kahn OI, Sharma V, Gonzalez-Billault C, Baas PW. Effects of kinesin-5 inhibition on dendritic architecture and microtubule organization. Mol Biol Cell 26(1): 66-77 (2015).